Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 50 entries
Sorted by: Best Match Show Resources per page
Translocated microbiome composition determines immunological outcome in treated HIV infection.

Cell

Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, Chipman JG, Beilman GJ, Hoskuldsson T, Fourati S, Schmidt TE, Arumugam S, Lima NS, Moon D, Callisto S, Schoephoerster J, Tomalka J, Mugyenyi P, Ssali F, Muloma P, Ssengendo P, Leda AR, Cheu RK, Flynn JK, Morou A, Brunet-Ratnasingham E, Rodriguez B, Lederman MM, Kaufmann DE, Klatt NR, Kityo C, Brenchley JM, Schacker TW, Sekaly RP, Douek DC.
PMID: 34237254
Cell. 2021 Jul 22;184(15):3899-3914.e16. doi: 10.1016/j.cell.2021.05.023. Epub 2021 Jul 07.

The impact of the microbiome on HIV disease is widely acknowledged although the mechanisms downstream of fluctuations in microbial composition remain speculative. We detected rapid, dynamic changes in translocated microbial constituents during two years after cART initiation. An unbiased...

Cite
Nganou-Makamdop K, Talla A, Sharma AA, et al. Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell. 2021;184(15):3899-3914.e16doi: 10.1016/j.cell.2021.05.023.
Nganou-Makamdop, K., Talla, A., Sharma, A. A., Darko, S., Ransier, A., Laboune, F., Chipman, J. G., Beilman, G. J., Hoskuldsson, T., Fourati, S., Schmidt, T. E., Arumugam, S., Lima, N. S., Moon, D., Callisto, S., Schoephoerster, J., Tomalka, J., Mugyenyi, P., Ssali, F., Muloma, P., Ssengendo, P., Leda, A. R., Cheu, R. K., Flynn, J. K., Morou, A., Brunet-Ratnasingham, E., Rodriguez, B., Lederman, M. M., Kaufmann, D. E., Klatt, N. R., Kityo, C., Brenchley, J. M., Schacker, T. W., Sekaly, R. P., & Douek, D. C. (2021). Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell, 184(15), 3899-3914.e16. https://doi.org/10.1016/j.cell.2021.05.023
Nganou-Makamdop, Krystelle, et al. "Translocated microbiome composition determines immunological outcome in treated HIV infection." Cell vol. 184,15 (2021): 3899-3914.e16. doi: https://doi.org/10.1016/j.cell.2021.05.023
Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, Chipman JG, Beilman GJ, Hoskuldsson T, Fourati S, Schmidt TE, Arumugam S, Lima NS, Moon D, Callisto S, Schoephoerster J, Tomalka J, Mugyenyi P, Ssali F, Muloma P, Ssengendo P, Leda AR, Cheu RK, Flynn JK, Morou A, Brunet-Ratnasingham E, Rodriguez B, Lederman MM, Kaufmann DE, Klatt NR, Kityo C, Brenchley JM, Schacker TW, Sekaly RP, Douek DC. Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell. 2021 Jul 22;184(15):3899-3914.e16. doi: 10.1016/j.cell.2021.05.023. Epub 2021 Jul 07. PMID: 34237254; PMCID: PMC8316372.
Copy Download .nbib Format: NLM
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.

Cell host & microbe

Chen RE, Smith BK, Errico JM, Gordon DN, Winkler ES, VanBlargan LA, Desai C, Handley SA, Dowd KA, Amaro-Carambot E, Cardosa MJ, Sariol CA, Kallas EG, Sékaly RP, Vasilakis N, Fremont DH, Whitehead SS, Pierson TC, Diamond MS.
PMID: 34610295
Cell Host Microbe. 2021 Nov 10;29(11):1634-1648.e5. doi: 10.1016/j.chom.2021.09.006. Epub 2021 Oct 04.

Although divergent dengue viruses (DENVs) have been isolated in insects, nonhuman primates, and humans, their relationships to the four canonical serotypes (DENV 1-4) are poorly understood. One virus isolated from a dengue patient, DKE-121, falls between genotype and serotype...

Cite
Chen RE, Smith BK, Errico JM, et al. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021;29(11):1634-1648.e5doi: 10.1016/j.chom.2021.09.006.
Chen, R. E., Smith, B. K., Errico, J. M., Gordon, D. N., Winkler, E. S., VanBlargan, L. A., Desai, C., Handley, S. A., Dowd, K. A., Amaro-Carambot, E., Cardosa, M. J., Sariol, C. A., Kallas, E. G., Sékaly, R. P., Vasilakis, N., Fremont, D. H., Whitehead, S. S., Pierson, T. C., & Diamond, M. S. (2021). Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell host & microbe, 29(11), 1634-1648.e5. https://doi.org/10.1016/j.chom.2021.09.006
Chen, Rita E, et al. "Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity." Cell host & microbe vol. 29,11 (2021): 1634-1648.e5. doi: https://doi.org/10.1016/j.chom.2021.09.006
Chen RE, Smith BK, Errico JM, Gordon DN, Winkler ES, VanBlargan LA, Desai C, Handley SA, Dowd KA, Amaro-Carambot E, Cardosa MJ, Sariol CA, Kallas EG, Sékaly RP, Vasilakis N, Fremont DH, Whitehead SS, Pierson TC, Diamond MS. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity. Cell Host Microbe. 2021 Nov 10;29(11):1634-1648.e5. doi: 10.1016/j.chom.2021.09.006. Epub 2021 Oct 04. PMID: 34610295; PMCID: PMC8595868.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ.
PMID: 33693561
Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212.

BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal...

Cite
Marconi VC, Moser C, Gavegnano C, et al. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022;74(1):95-104doi: 10.1093/cid/ciab212.
Marconi, V. C., Moser, C., Gavegnano, C., Deeks, S. G., Lederman, M. M., Overton, E. T., Tsibris, A., Hunt, P. W., Kantor, A., Sekaly, R. P., Tressler, R., Flexner, C., Hurwitz, S. J., Moisi, D., Clagett, B., Hardin, W. R., Del Rio, C., Schinazi, R. F., & Lennox, J. J. (2022). Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(1), 95-104. https://doi.org/10.1093/cid/ciab212
Marconi, Vincent C, et al. "Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 74,1 (2022): 95-104. doi: https://doi.org/10.1093/cid/ciab212
Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212. PMID: 33693561; PMCID: PMC8752257.
Copy Download .nbib Format: NLM
Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use.

Journal of acquired immune deficiency syndromes (1999)

Routy JP, Vanhems P, Rouleau D, Tsoukas C, Lefèbvre E, Côté P, LeBlanc R, Conway B, Alary M, Bruneau J, Sekaly RP.
PMID: 11103037
J Acquir Immune Defic Syndr. 2000 Aug 15;24(4):425-432.

Acute HIV-1 infection (AHI) may present with a clinical picture that represents a diagnostic challenge. We tested the hypothesis that two different routes of infection, that is, sexual versus parenteral, might be associated with a difference in the clinical...

Cite
Routy JP, Vanhems P, Rouleau D, et al. Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use. J Acquir Immune Defic Syndr. 2000;24(4):425-432
Routy, J. P., Vanhems, P., Rouleau, D., Tsoukas, C., Lefèbvre, E., Côté, P., LeBlanc, R., Conway, B., Alary, M., Bruneau, J., & Sekaly, R. P. (2000). Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use. Journal of acquired immune deficiency syndromes (1999), 24(4), 425-432.
Routy, et al. "Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use." Journal of acquired immune deficiency syndromes (1999) vol. 24,4 (2000): 425-432.
Routy JP, Vanhems P, Rouleau D, Tsoukas C, Lefèbvre E, Côté P, LeBlanc R, Conway B, Alary M, Bruneau J, Sekaly RP. Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use. J Acquir Immune Defic Syndr. 2000 Aug 15;24(4):425-432. PMID: 11103037.
Copy Download .nbib Format: NLM
Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation.

Frontiers in immunology

Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, Levine AD, Weinberg A, Sekaly RP.
PMID: 27379092
Front Immunol. 2016 Jun 20;7:228. doi: 10.3389/fimmu.2016.00228. eCollection 2016.

Residual mucosal inflammation along with chronic systemic immune activation is an important feature in individuals infected with human immunodeficiency virus (HIV), and has been linked to a wide range of co-morbidities, including malignancy, opportunistic infections, immunopathology, and cardiovascular complications....

Cite
Pandiyan P, Younes SA, Ribeiro SP, et al. Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation. Front Immunol. 2016;7:228doi: 10.3389/fimmu.2016.00228.
Pandiyan, P., Younes, S. A., Ribeiro, S. P., Talla, A., McDonald, D., Bhaskaran, N., Levine, A. D., Weinberg, A., & Sekaly, R. P. (2016). Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation. Frontiers in immunology, 7228. https://doi.org/10.3389/fimmu.2016.00228
Pandiyan, Pushpa, et al. "Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation." Frontiers in immunology vol. 7 (2016): 228. doi: https://doi.org/10.3389/fimmu.2016.00228
Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, Levine AD, Weinberg A, Sekaly RP. Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation. Front Immunol. 2016 Jun 20;7:228. doi: 10.3389/fimmu.2016.00228. eCollection 2016. PMID: 27379092; PMCID: PMC4913236.
Copy Download .nbib Format: NLM
Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection.

Translational research : the journal of laboratory and clinical medicine

Latif MB, Shukla S, Estrada PMDR, Ribeiro SP, Sekaly RP, Sharma AA.
PMID: 34871809
Transl Res. 2021 Dec 03; doi: 10.1016/j.trsl.2021.12.001. Epub 2021 Dec 03.

Patients with cancers have been severely affected by the COVID-19 pandemic. This is highlighted by the adverse outcomes in cancer patients with COVID-19 as well as by the impact of the COVID-19 pandemic on cancer care. Patients with cancer...

Cite
Latif MB, Shukla S, Estrada PMDR, et al. Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res. 2021;doi: 10.1016/j.trsl.2021.12.001.
Latif, M. B., Shukla, S., Estrada, P. M. D. R., Ribeiro, S. P., Sekaly, R. P., & Sharma, A. A. (2021). Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Translational research : the journal of laboratory and clinical medicine, . https://doi.org/10.1016/j.trsl.2021.12.001
Latif, Muhammad Bilal, et al. "Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection." Translational research : the journal of laboratory and clinical medicine vol. (2021). doi: https://doi.org/10.1016/j.trsl.2021.12.001
Latif MB, Shukla S, Estrada PMDR, Ribeiro SP, Sekaly RP, Sharma AA. Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection. Transl Res. 2021 Dec 03; doi: 10.1016/j.trsl.2021.12.001. Epub 2021 Dec 03. PMID: 34871809; PMCID: PMC8641406.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.

Frontiers in immunology

Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, Boughan K, Hillian A, Reese-Koc J, Maschan M, Dropulic B, Sekaly RP, de Lima M.
PMID: 34712233
Front Immunol. 2021 Oct 12;12:745320. doi: 10.3389/fimmu.2021.745320. eCollection 2021.

Anti-CD19 chimeric antigen receptor T (CAR-T) cells have demonstrated activity against relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell - associated neurotoxicity syndrome (ICANS) are well-known complications. Tocilizumab, a monoclonal antibody targeting the interleukin-6 (IL-6) receptor was...

Cite
Caimi PF, Pacheco Sanchez G, Sharma A, et al. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Front Immunol. 2021;12:745320doi: 10.3389/fimmu.2021.745320.
Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., Boughan, K., Hillian, A., Reese-Koc, J., Maschan, M., Dropulic, B., Sekaly, R. P., & de Lima, M. (2021). Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Frontiers in immunology, 12745320. https://doi.org/10.3389/fimmu.2021.745320
Caimi, Paolo F, et al. "Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma." Frontiers in immunology vol. 12 (2021): 745320. doi: https://doi.org/10.3389/fimmu.2021.745320
Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, Boughan K, Hillian A, Reese-Koc J, Maschan M, Dropulic B, Sekaly RP, de Lima M. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. Front Immunol. 2021 Oct 12;12:745320. doi: 10.3389/fimmu.2021.745320. eCollection 2021. PMID: 34712233; PMCID: PMC8546323.
Copy Download .nbib Format: NLM
Cocaethylene, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV.

Drug and alcohol dependence

Tamargo JA, Sherman KE, Sékaly RP, Bordi R, Schlatzer D, Lai S, Khalsa JH, Mandler RN, Ehman RL, Baum MK.
PMID: 35033954
Drug Alcohol Depend. 2022 Jan 12;232:109273. doi: 10.1016/j.drugalcdep.2022.109273. Epub 2022 Jan 12.

BACKGROUND: The simultaneous consumption of cocaine and alcohol results in the production of cocaethylene (CE) in the liver, a highly toxic metabolite. Prior research suggests that cocaine use contributes to liver disease and its concomitant use with alcohol may...

Cite
Tamargo JA, Sherman KE, Sékaly RP, et al. Cocaethylene, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV. Drug Alcohol Depend. 2022;232:109273doi: 10.1016/j.drugalcdep.2022.109273.
Tamargo, J. A., Sherman, K. E., Sékaly, R. P., Bordi, R., Schlatzer, D., Lai, S., Khalsa, J. H., Mandler, R. N., Ehman, R. L., & Baum, M. K. (2022). Cocaethylene, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV. Drug and alcohol dependence, 232109273. https://doi.org/10.1016/j.drugalcdep.2022.109273
Tamargo, Javier A, et al. "Cocaethylene, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV." Drug and alcohol dependence vol. 232 (2022): 109273. doi: https://doi.org/10.1016/j.drugalcdep.2022.109273
Tamargo JA, Sherman KE, Sékaly RP, Bordi R, Schlatzer D, Lai S, Khalsa JH, Mandler RN, Ehman RL, Baum MK. Cocaethylene, simultaneous alcohol and cocaine use, and liver fibrosis in people living with and without HIV. Drug Alcohol Depend. 2022 Jan 12;232:109273. doi: 10.1016/j.drugalcdep.2022.109273. Epub 2022 Jan 12. PMID: 35033954.
Copy Download .nbib Format: NLM
Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.

bioRxiv : the preprint server for biology

Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MY, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Weiskopf D, Filev PD, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M.
PMID: 32995780
bioRxiv. 2020 Sep 16; doi: 10.1101/2020.09.16.300277.

Effective therapeutics aimed at mitigating COVID-19 symptoms are urgently needed. SARS-CoV-2 induced hypercytokinemia and systemic inflammation are associated with disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor with potent anti-inflammatory properties is currently being investigated in COVID-19 human clinical...

Cite
Hoang TN, Pino M, Boddapati AK, et al. Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. bioRxiv. 2020;doi: 10.1101/2020.09.16.300277.
Hoang, T. N., Pino, M., Boddapati, A. K., Viox, E. G., Starke, C. E., Upadhyay, A. A., Gumber, S., Busman-Sahay, K., Strongin, Z., Harper, J. L., Tharp, G. K., Pellegrini, K. L., Kirejczyk, S., Zandi, K., Tao, S., Horton, T. R., Beagle, E. N., Mahar, E. A., Lee, M. Y., Cohen, J., Jean, S. M., Wood, J. S., Connor-Stroud, F., Stammen, R. L., Delmas, O. M., Wang, S., Cooney, K. A., Sayegh, M. N., Wang, L., Weiskopf, D., Filev, P. D., Waggoner, J., Piantadosi, A., Kasturi, S. P., Al-Shakhshir, H., Ribeiro, S. P., Sekaly, R. P., Levit, R. D., Estes, J. D., Vanderford, T. H., Schinazi, R. F., Bosinger, S. E., & Paiardini, M. (2020). Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.09.16.300277
Hoang, Timothy N, et al. "Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.09.16.300277
Hoang TN, Pino M, Boddapati AK, Viox EG, Starke CE, Upadhyay AA, Gumber S, Busman-Sahay K, Strongin Z, Harper JL, Tharp GK, Pellegrini KL, Kirejczyk S, Zandi K, Tao S, Horton TR, Beagle EN, Mahar EA, Lee MY, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Delmas OM, Wang S, Cooney KA, Sayegh MN, Wang L, Weiskopf D, Filev PD, Waggoner J, Piantadosi A, Kasturi SP, Al-Shakhshir H, Ribeiro SP, Sekaly RP, Levit RD, Estes JD, Vanderford TH, Schinazi RF, Bosinger SE, Paiardini M. Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques. bioRxiv. 2020 Sep 16; doi: 10.1101/2020.09.16.300277. PMID: 32995780; PMCID: PMC7523106.
Copy Download .nbib Format: NLM
Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Current opinion in virology

Pelletier AN, Sekaly RP, Tomalka JA.
PMID: 34902803
Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10.

The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls...

Cite
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021;52:89-101doi: 10.1016/j.coviro.2021.11.012.
Pelletier, A. N., Sekaly, R. P., & Tomalka, J. A. (2021). Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Current opinion in virology, 5289-101. https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier, Adam N, et al. "Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines." Current opinion in virology vol. 52 (2021): 89-101. doi: https://doi.org/10.1016/j.coviro.2021.11.012
Pelletier AN, Sekaly RP, Tomalka JA. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. Curr Opin Virol. 2021 Dec 10;52:89-101. doi: 10.1016/j.coviro.2021.11.012. Epub 2021 Dec 10. PMID: 34902803; PMCID: PMC8664555.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 50 entries